Self-rated cognitive functions following chemotherapy in patients with breast cancer

A 6-month prospective study

Ryosuke Kitahata, Shinichiro Nakajima, Hiroyuki Uchida, Tetsu Hayashida, Maiko Takahashi, Shintaro Nio, Jinichi Hirano, Maki Nagaoka, Takefumi Suzuki, Hiromitsu Jinno, Yuukou Kitagawa, Masaru Mimura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The purpose of the study was to evaluate subjective (self-rated), family-rated, and objective (researcher-rated) cognitive functions in patients with breast cancer after chemotherapy. Method: We conducted a prospective study to trace self-rated cognitive functions in 30 patients with breast cancer at the completion of chemotherapy (T0) and 6 months later (T1). Subjective cognitive functions were assessed with Cognitive Failures Questionnaire (CFQ), Dysexecutive Questionnaire (DEX-S), and Everyday Memory Checklist (EMC-S) for attention, executive function, and episodic memory, respectively. Their family members also completed DEX-I and EMC-I for executive function and episodic memory, respectively. We also examined objective cognitive functions. Self-rated cognitive functions were compared with the normative data. They were compared between T0 and T1. We calculated correlation coefficients between self-rated and other cognitive functions. Results: At T0, 6 (20.0%) and 2 (6.7%) participants showed higher DEX-S and EMC-S scores than the normative data, respectively, while no participant had abnormal CFQ scores. At T1, DEX-S and EMC-S scores were normalized in 3 (50.0%) and 2 (100.0%) participants, respectively. No participant showed increases in CFQ scores. No changes were found in objective cognitive functions from T0 to T1. DEX-S and DEX-I or EMC-S and EMC-I scores were correlated at both T0 and T1, which did not survive multiple corrections. There was no association between subjective and objective cognitive functions. Conclusion: Impairments in subjective cognition may be transient after chemotherapy in patients with breast cancer. Furthermore, patients and their families appear to share similar prospects on their cognitive functions.

Original languageEnglish
Pages (from-to)2489-2496
Number of pages8
JournalNeuropsychiatric Disease and Treatment
Volume13
DOIs
Publication statusPublished - 2017 Oct 3

Fingerprint

Cognition
Prospective Studies
Breast Neoplasms
Drug Therapy
Checklist
Episodic Memory
Executive Function
Surveys and Questionnaires
Research Personnel

Keywords

  • Breast cancer
  • Chemotherapy
  • Subjective cognitive functions

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{98de0ba58ae64e2f888a4f68fcb2d850,
title = "Self-rated cognitive functions following chemotherapy in patients with breast cancer: A 6-month prospective study",
abstract = "Purpose: The purpose of the study was to evaluate subjective (self-rated), family-rated, and objective (researcher-rated) cognitive functions in patients with breast cancer after chemotherapy. Method: We conducted a prospective study to trace self-rated cognitive functions in 30 patients with breast cancer at the completion of chemotherapy (T0) and 6 months later (T1). Subjective cognitive functions were assessed with Cognitive Failures Questionnaire (CFQ), Dysexecutive Questionnaire (DEX-S), and Everyday Memory Checklist (EMC-S) for attention, executive function, and episodic memory, respectively. Their family members also completed DEX-I and EMC-I for executive function and episodic memory, respectively. We also examined objective cognitive functions. Self-rated cognitive functions were compared with the normative data. They were compared between T0 and T1. We calculated correlation coefficients between self-rated and other cognitive functions. Results: At T0, 6 (20.0{\%}) and 2 (6.7{\%}) participants showed higher DEX-S and EMC-S scores than the normative data, respectively, while no participant had abnormal CFQ scores. At T1, DEX-S and EMC-S scores were normalized in 3 (50.0{\%}) and 2 (100.0{\%}) participants, respectively. No participant showed increases in CFQ scores. No changes were found in objective cognitive functions from T0 to T1. DEX-S and DEX-I or EMC-S and EMC-I scores were correlated at both T0 and T1, which did not survive multiple corrections. There was no association between subjective and objective cognitive functions. Conclusion: Impairments in subjective cognition may be transient after chemotherapy in patients with breast cancer. Furthermore, patients and their families appear to share similar prospects on their cognitive functions.",
keywords = "Breast cancer, Chemotherapy, Subjective cognitive functions",
author = "Ryosuke Kitahata and Shinichiro Nakajima and Hiroyuki Uchida and Tetsu Hayashida and Maiko Takahashi and Shintaro Nio and Jinichi Hirano and Maki Nagaoka and Takefumi Suzuki and Hiromitsu Jinno and Yuukou Kitagawa and Masaru Mimura",
year = "2017",
month = "10",
day = "3",
doi = "10.2147/NDT.S141408",
language = "English",
volume = "13",
pages = "2489--2496",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Self-rated cognitive functions following chemotherapy in patients with breast cancer

T2 - A 6-month prospective study

AU - Kitahata, Ryosuke

AU - Nakajima, Shinichiro

AU - Uchida, Hiroyuki

AU - Hayashida, Tetsu

AU - Takahashi, Maiko

AU - Nio, Shintaro

AU - Hirano, Jinichi

AU - Nagaoka, Maki

AU - Suzuki, Takefumi

AU - Jinno, Hiromitsu

AU - Kitagawa, Yuukou

AU - Mimura, Masaru

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Purpose: The purpose of the study was to evaluate subjective (self-rated), family-rated, and objective (researcher-rated) cognitive functions in patients with breast cancer after chemotherapy. Method: We conducted a prospective study to trace self-rated cognitive functions in 30 patients with breast cancer at the completion of chemotherapy (T0) and 6 months later (T1). Subjective cognitive functions were assessed with Cognitive Failures Questionnaire (CFQ), Dysexecutive Questionnaire (DEX-S), and Everyday Memory Checklist (EMC-S) for attention, executive function, and episodic memory, respectively. Their family members also completed DEX-I and EMC-I for executive function and episodic memory, respectively. We also examined objective cognitive functions. Self-rated cognitive functions were compared with the normative data. They were compared between T0 and T1. We calculated correlation coefficients between self-rated and other cognitive functions. Results: At T0, 6 (20.0%) and 2 (6.7%) participants showed higher DEX-S and EMC-S scores than the normative data, respectively, while no participant had abnormal CFQ scores. At T1, DEX-S and EMC-S scores were normalized in 3 (50.0%) and 2 (100.0%) participants, respectively. No participant showed increases in CFQ scores. No changes were found in objective cognitive functions from T0 to T1. DEX-S and DEX-I or EMC-S and EMC-I scores were correlated at both T0 and T1, which did not survive multiple corrections. There was no association between subjective and objective cognitive functions. Conclusion: Impairments in subjective cognition may be transient after chemotherapy in patients with breast cancer. Furthermore, patients and their families appear to share similar prospects on their cognitive functions.

AB - Purpose: The purpose of the study was to evaluate subjective (self-rated), family-rated, and objective (researcher-rated) cognitive functions in patients with breast cancer after chemotherapy. Method: We conducted a prospective study to trace self-rated cognitive functions in 30 patients with breast cancer at the completion of chemotherapy (T0) and 6 months later (T1). Subjective cognitive functions were assessed with Cognitive Failures Questionnaire (CFQ), Dysexecutive Questionnaire (DEX-S), and Everyday Memory Checklist (EMC-S) for attention, executive function, and episodic memory, respectively. Their family members also completed DEX-I and EMC-I for executive function and episodic memory, respectively. We also examined objective cognitive functions. Self-rated cognitive functions were compared with the normative data. They were compared between T0 and T1. We calculated correlation coefficients between self-rated and other cognitive functions. Results: At T0, 6 (20.0%) and 2 (6.7%) participants showed higher DEX-S and EMC-S scores than the normative data, respectively, while no participant had abnormal CFQ scores. At T1, DEX-S and EMC-S scores were normalized in 3 (50.0%) and 2 (100.0%) participants, respectively. No participant showed increases in CFQ scores. No changes were found in objective cognitive functions from T0 to T1. DEX-S and DEX-I or EMC-S and EMC-I scores were correlated at both T0 and T1, which did not survive multiple corrections. There was no association between subjective and objective cognitive functions. Conclusion: Impairments in subjective cognition may be transient after chemotherapy in patients with breast cancer. Furthermore, patients and their families appear to share similar prospects on their cognitive functions.

KW - Breast cancer

KW - Chemotherapy

KW - Subjective cognitive functions

UR - http://www.scopus.com/inward/record.url?scp=85031126583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031126583&partnerID=8YFLogxK

U2 - 10.2147/NDT.S141408

DO - 10.2147/NDT.S141408

M3 - Article

VL - 13

SP - 2489

EP - 2496

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -